
Piezolabs Medical is engineering a low-profile, Trans-Venous Valve Replacement Approach — Leaflets is made from a novel polymer material manufactured through proprietary process to keep one-way flow to restore normal venous function.

Patients with advanced chronic venous insufficiency can face swelling, pain, recurrent ulcers, reduced mobility, and high long-term care burden. Existing approaches often do not restore native valve function.
Severe Symptoms
Edema, venous hypertension, pain, and skin breakdown.
Recurring Ulcers
Slow healing and repeated
US Adults with CVI
More than 25 million adults affected nationwide
Advanced disease
Around 6M Living with advanced stages of venous disease
Venous ulcers
More than 500K Americans with painful, slow-healing venous ulcers (CEAP C5–C6)
Estimated annual cost
$90B Estimated annual cost of CVI to the US healthcare sy
The Piezolabs approach has advanced beyond concept development, with animal-study validation supporting the core design principles and informing the next stage of development.
Focus on severe venous valve failure where native function is not restored.
"Flow Field designed together rather than independently. Animal data used to validate design principles and refine the development roadmap.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.